Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Market Cap	11.68B -17.5%
Revenue (ttm)	2.82B +11.0%
Net Income	409.03M -21.8%
EPS	6.07 -22.1%
Shares Out	66.89M
PE Ratio	28.78
Forward PE	n/a
Dividend	2.50 (1.43%)
Ex-Dividend Date	Sep 12, 2025

Volume	144,925
Average Volume	65,095
Open	176.50
Previous Close	174.56
Day's Range	172.25 - 178.76
52-Week Range	155.00 - 301.65
Beta	-0.44
RSI	46.89
Earnings Date	Jan 21, 2026

About Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 1,399
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: JAGSNPHARM

Financial Performance

In fiscal year 2025, Jagsonpal Pharmaceuticals's revenue was 2.69 billion, an increase of 28.76% compared to the previous year's 2.09 billion. Earnings were 553.61 million, an increase of 146.45%.